Keybank National Association OH Lowers Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Keybank National Association OH decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 51.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,102 shares of the medical research company's stock after selling 2,226 shares during the quarter. Keybank National Association OH's holdings in Charles River Laboratories International were worth $388,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Principal Financial Group Inc. raised its holdings in Charles River Laboratories International by 3.6% during the 3rd quarter. Principal Financial Group Inc. now owns 60,501 shares of the medical research company's stock valued at $11,917,000 after buying an additional 2,126 shares during the period. Assetmark Inc. raised its stake in shares of Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after acquiring an additional 173 shares during the period. Covestor Ltd lifted its holdings in shares of Charles River Laboratories International by 40.9% in the 3rd quarter. Covestor Ltd now owns 327 shares of the medical research company's stock worth $65,000 after acquiring an additional 95 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in shares of Charles River Laboratories International by 61.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 1,616 shares of the medical research company's stock worth $318,000 after purchasing an additional 614 shares during the period. Finally, WCM Investment Management LLC grew its holdings in Charles River Laboratories International by 33.3% during the 3rd quarter. WCM Investment Management LLC now owns 10,367 shares of the medical research company's stock valued at $2,056,000 after purchasing an additional 2,589 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on CRL shares. Bank of America cut their target price on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a research note on Friday, December 13th. Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price on the stock in a research note on Monday, March 3rd. UBS Group reissued a "neutral" rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. CLSA downgraded shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target on the stock. in a research note on Monday, November 18th. Finally, Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their target price for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $198.36.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO James C. Foster purchased 6,075 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Stock Up 2.6 %

NYSE:CRL traded up $4.34 during midday trading on Friday, reaching $171.27. 1,033,768 shares of the stock traded hands, compared to its average volume of 709,529. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $274.77. The business has a 50-day moving average of $168.35 and a two-hundred day moving average of $185.07. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a market capitalization of $8.76 billion, a PE ratio of 1,141.78, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm's quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.46 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).